Venker Eric 4

What Happened

• Eric Venker, CEO of Immunovant (IMVT), received equity awards on April 7, 2026: 232,252 restricted stock units (RSUs) and 336,043 stock options. Both awards were granted at $0.00 (no cash paid at grant) as reported on Form 4 (transaction code A — award/grant).

Key Details

• Transaction date: 2026-04-07; filing date: 2026-04-09 (filed timely).
• RSUs: 232,252 units; each RSU converts to one share upon vesting. Vesting: 25% on April 1, 2027, then the remainder in 12 substantially equal quarterly installments (footnote F1); subject to continuous service.
• Options: 336,043 options (derivative award); vesting: 25% on April 1, 2027, then the remainder in 36 substantially equal monthly installments (footnote F2); subject to continuous service.
• Acquisition price shown: $0.00 for both grants.
• Shares owned following the transaction: not specified in the information provided in this filing.

Context

• RSUs are a contingent right to receive shares upon vesting; options are rights to purchase shares subject to vesting. These are standard equity compensation grants under the Issuer's 2019 Equity Incentive Plan and do not indicate a market sale or purchase by the insider.